<DOC>
	<DOC>NCT02551549</DOC>
	<brief_summary>A multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CD101 Injection in Healthy Subjects.</brief_summary>
	<brief_title>An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects</brief_title>
	<detailed_description>This is a Phase 1, single-center, prospective, randomized, double-blind study of multiple ascending doses (MAD) of CD101 Injection administered IV to healthy adult subjects. In this study, subjects in 3 cohorts of 8 subjects each will be randomized to receive multiple IV doses of CD101 Injection or placebo infusions. Dose levels of CD101 Injection to be assessed will follow an ascending multiple-dose regimen.</detailed_description>
	<criteria>Men must be surgically sterilized or using contraception, No significant findings on physical exam, ECG, clinical laboratory tests, Body mass index (BMI) between 18.5 and 32.0 kg/m2, inclusive Must provide written informed consent Females of child bearing potential Signs and or symptoms of acute illness or chronic disease Use of prescription medications within 28 days Use of OTC, supplements, and herbals within 14 days Current smoker Previous participation in a clinical study within 28 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Subjects</keyword>
</DOC>